Joern S. Jakobsen

Oncologic Urologist,

[Joern S. Jakobsen @UroDocJSJ]

Hopefully this opening from the EMA will further help patients in Europe to have equal access to treatments for oncological diseases as they seem to move in the direction of accepting single arms trials in unique patient populations. https://t.co/rpKDuNHIq7

[Joern S. Jakobsen @UroDocJSJ]

Wonderful end of week.
#Ferring #Adstiladrin #SUO #Bladdercancer https://t.co/utwfrNz0Rj

[Ferring Pharmaceuticals @ferring]

@US_FDA announced approval of Adstiladrin®, a novel adenovirus vector-based gene therapy, for treatment of adults for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
https://t.co/zt9eHaLzLv
#Ferring

[Joern S. Jakobsen @UroDocJSJ]

@pcvblack @ManitobaUrology @RahulBansal_13 @JayNayakMD @PremalPatelMD Indeed @pcvblack 💪🏻.

[Mikkel Fode @MikkelFode]

Danish authorities decided to include an andrology consultant for the design of new road markings. 🤞That the trend spreads 😀 #UroSoMe

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial https://t.co/lfejDBePFf

[Joern S. Jakobsen @UroDocJSJ]

@gpalapa2 Happy B-day 🕺🏼🎤

[Joan Palou Redorta @joanfundi]

Bcg failure? Multiple options and more in the future! Be ready!

[Joern S. Jakobsen @UroDocJSJ]

@UroDocAsh @NatRevUrol @DebSundi @joanfundi @EurUrolOncol @AmerUrological @SUO_YUO @BladderCancerUS @UroDocAsh @Uroweb @EAU_Uroonco
Will be important to look at outcomes of evolving competitors in the #BCG-Unresponsive field in the near future looking for safe alternatives for patients

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Thanks for this @NatRevUrol
Relevant especially today when BCG #DrugShortage

@DebSundi @joanfundi @EurUrolOncol @AmerUrological @SUO_YUO @BladderCancerUS

[IBCN @IBCN1997]

Abstract deadline approaching fast July 1st, 2019 for the 2019 Annual IBCN meeting October 3 – 5, 2019 in Aarhus, Denmark. Please visit https://t.co/rpJXoMhRgp… for abstract submission information. #IBCN2019 @pcvblack @UroDocAsh @Roland3097 @SWilliams_MD

[Peter Ostergren @PeterBOstergren]

Line Dohn from @HerlevGentofte gives overview of immunotherapy for bladdercancer #NUF2019. Well tolerated, but beware of servere AEs

[European Urology @EUplatinum]

Reviewing the role of the genitourinary and gastrointestinal microbiome in GU cancer initiation and treatment response https://t.co/4W00ufe0TA

[Drew Moghanaki @DrewMoghanaki]

LIFE-RADS
1-all is fine
2-probably okay
3-you better watch it
4-you better do something
5-you’re gonne die!

[Joern S. Jakobsen @UroDocJSJ]

@UroDocAsh , @AStenzl
Take it away💪🏻

[Joern S. Jakobsen @UroDocJSJ]

@UroDocAsh @Uroweb @B_C_A_N @urotoday @EurUrolOncol @BrantInman @MRoupret @JimCatto @AStenzl @AlisonBirtle @MarekBabjuk @WesKassouf @PGrivasMDPhD @Agarwal_CaB @joanfundi @UroDocAsh
Looking forward💪🏻

[European Urology @EUplatinum]

The four major urology journals have joined forces to publish shared statistical guidelines for authors to follow https://t.co/g8HSVefhOG

[Joern S. Jakobsen @UroDocJSJ]

@UroDocAsh @AppleSupport Sorry to hear @UroDocAsh. Remember the 14 days I mentioned, and let others do the suffering 😊

[European Urology @EUplatinum]

The Microbiome and Genitourinary Cancer: A Collaborative Review https://t.co/4K878jP4ZS

[Joern S. Jakobsen @UroDocJSJ]

#Canadian Urological Association
Love your point.

[Joern S. Jakobsen @UroDocJSJ]

Great collaboration in the Nordic Countries:
400 ptt randomized so far. https://t.co/pPpY3I9Uy7